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Abstract 
As canine mammary tumours (CMT) and human breast cancer share clinical and prognostic features, the 
former have been proposed as a model to study carcinogenesis and improved therapeutic treatment in human 
breast cancer. In recent years, it has been shown that transient receptor potential vanilloid 1 (TRPV1) is 
expressed in different neoplastic tissues and its activation has been associated with regulation of cancer growth 
and progression. The aim of the present research was to demonstrate the presence of TRPV1 in human and 
canine mammary cancer cells, MCF-7 and CF.41, respectively, and to study the role of TRPV1 in regulating 
cell proliferation. The images obtained by Western blot showed a signal at 100 kDa corresponding to the 
molecular weight of TRPV1 receptor. All tested TRPV1 agonists and antagonists caused a significant decrease 
(P < 0.05) of cell growth rate in MCF-7 cells. By contrast, in CF.41 cells capsaicin and capsazepine induced a 
significant increase 
(P < 0.05) in cell proliferation, whereas resiniferatoxin (RTX) and 5-iodo-resiniferatoxin (5-I-RTX) had 
no influence on CF.41 cell proliferation. Further studies are needed to elucidate the underlying molecular 
mechanism responsible for the different effects evoked by TRPV1 activation in MCF-7 and CF.41 cells. 
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Introduction 
Recent epidemiological data suggest that in 2008 almost 1.4 million women worldwide were diagnosed with 
breast cancer and approximately 459 000 deaths were recorded. The 5-year relative survival rate ranges from 
12 to 90% depending on diagnostic and therapeutic approach.1 Similarly to humans, mammary glands are the 
most frequent site of neoplasia in female dogs and in this species mammary tumours represent one of the 
leading causes of death due to development of metastases in regional lymph nodes and lung.2 Clinical and 
molecular similarities between canine mammary tumours (CMT) and human breast cancer have been described 
in recent years.3 Interestingly, beside the fact that the etiopathogenesis of CMT is still unclear, by comparing 
breast cancer frequencies of dog and pet ownership a significant positive correlation was found.4 Indeed, the 
use of dogs spontaneously affected by cancer in trials testing novel anticancer therapies for humans, is growing 
up.5,6 As in humans, age, obesity and diet seem to increase the risk of CMT.7 Moreover, inbothspecies 
prognosis depends on tumour size, histology type, proliferation rate, lymph node status, hormonal receptor 
status, presence of metastases and gene expression profile.8 
The transient receptor potential vanilloid 1 (TRPV1) is a member of the transient receptor potential (TRP) 
family known to be expressed in several neural and non-neuronal tissues of dif- ferent animal species.9 TRPV1 
is a non-selective cation channel that can be activated either by physical, chemical and pro-inflammatory 
stimuli such as noxious heat (>43 ◦C), low pH (<6) or by different lipophilic compounds including capsaicin 
and phospholipid derivatives.10 The acti- vation of TRPV1 receptors causes calcium influx and the 
corresponding release of tachykinin neuropeptides which, in turn, trigger a tissue response known as 
‘neurogenic’ inflammation.11 In recent years, TRP channels have been associated with cancer growth and 
progression.12 Their expres- sion has been demonstrated in different neoplastic tissues such as squamous cell 
carcinoma of the human tongue,13 human prostate carcinoma,14 colon cancer,15 transitional carcinoma of 
human bladder16 and human breast cancer.17 Santoni et al.16 found that TRPV1 expression decreases during 
the development of transitional cell car- cinoma of human bladder and outlined its key role in the regulation 
of tumour cell proliferation and even as possible therapeutic target.16 Mammalian TRPV1 receptors were 
cloned and characterized in humans,18 rats,19 guinea pigs,20 rabbits,21 mice22 and dogs.23 The various 
TRPV1-homologues share a conserved structure composed by six transmem- brane spanning domains (S1 – 
S6), intracellular N and C terminals and a pore-forming hydrophobic stretch between the fifth and the sixth 
domains. TRPV1 receptors are activated by vanilloids-like capsaicin. However, TRPV1 proteins do not always 
exhibit the same pharmacological profile. While in rat 12-phenyl-acetate 13-acetate 20-homovanillate 
(PPAHV) acts as a potent agonist for TRPV1, in humans and guinea pig TRPV1s are not stimulated by 
PPAHV.24,25 
As mentioned previously, the canine model is currently used in comparative oncology as spontaneous tumours 
in dogs share a wide variety of epidemiological, biological and clinical features with human cancers, which 
make this animal model attractive in oncology research.26 In past decades, dog was studied as a model for 
prostate tumour,27 osteosarcoma,28 lymphoma29,30 and mammary tumour.26,31 Considering that TRPV1 is 
expressed both in human and canine species and it is expressed in human breast cancer, the aim of the present 
research was to study the expression of TRPV1 receptor in cells derived from human breast cancer and canine 
mammary cancer. Moreover, the pharmacological characteristics of different specific TRPV1 agonists and 
antagonists were studiedthroughproliferationassays inorderto evaluate the capacity of TRPV1 ligands to 
modulate the growth of tumour cells. 
 
Materials and methods 
Cell culture 
MCF-7 cells (cells derived from pleural effusion after pleural methastatization of human breast 
adenocarcinoma, ATCC cell culture, LGC Stan- dards, Milan, Italy) and CF.41 cells (cells derived from canine 
mammary adenocarcinoma, ATCC cell culture, LGC Standards, Milan, Italy) were cultured in 75 cm3 flasks 
containing Dulbecco’s Modified Eagles Medium (DMEM, Lonza, Basel, Switzerland) supplemented with 20% 
Fetal Bovine Serum (FBS, Sigma Aldrich, Milan, Italy), 2% penicilllin– streptomicin– amphotericin B solution 
(Sigma Aldrich) and 2% L-glutamine (Sigma Aldrich) at 37 ◦C with 5% CO2, 95% air and com- plete 
humidity. When reaching a confluence of 80%, cells were detached using 0.1% Trypsin/EDTA solution (Sigma 
Aldrich), centrifuged and counted using Trypan Blue solution (Sigma Aldrich) with a Burker chamber. Cells 
were then resuspended at a concentration of 5 × 105 cells mL−1 and seeded at the same conditions mentioned 
before. 
 
Western blotting assay 
Thawed cells (concentration 180 × 106 cells approx- imately), re-suspended in binding buffer (KCl 5 mM, 
NaCl 5.8 mM, CaCl2 0.75 mM, MgCl2 2 mM, sucrose 320 mM and Hepes 10 mM, pH 7.4, Sigma Aldrich), 
were disrupted using a soni- cator (XL 2020, Misonix, Farmingdale, NY, USA) and centrifuged at 3000 × g 
for 10 min at 4 ◦C. The resulting surnatants were ultra centrifuged at 105 000 × g for 45 min at 4 ◦C to separate 
cytoso- lic fraction from cell membrane fraction. The final pellets were suspended in the same buffer and the 
protein concentration was measured according to the method described by Lowry et al.32 Samples were loaded 
at 25, 50 and 100 g mL−1 of pro- tein per lane and subjected to sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS- PAGE) procedure using 8% Acrylamide (Biosolve, Valkenswaand, The Netherlands) 
gel. A proteic lysate of urinary rat bladder was used as positive control. Samples were then transferred to nitro- 
cellulose membranes (Hybond ECL, Amersham, GE Healthcare, Milan, Italy). After being washed three times, 
samples were probed with the primary anti-TRPV1 antibody (goat polyclonal antibody, Santa Cruz 
Biotechnology, Heidelberg, Germany) (dilution 1:100) and incubated overnight at 5 ◦C on a shaking plate. At 
the end of the incubation period samples were washed again for four times and probed with the secondary 
antibody (donkey anti-goat IgG– HRP, Santa Cruz Biotechnology) (dilution 1:15 000) for 1 h. Secondary 
antibody was removed by fourwashes andimmunoreactive bands were visualized by enhanced 
chemiluminescence (ECL-Plus System, Amersham, GE Healthcare). To obtain an endogenous control, 
membranes were washed and re-probed with β-actin antibody (dilu- tion 1:100, Santa Cruz Biotechnology) for 
1 h. Also, in this case the immunoreactive bands of β- actin were visualized by ECL (ECL-Plus System, 
Amersham, GE Healthcare). 
 
Proliferation assays 
3-(4,5-Dimethylthiazol-2-yl)-2,5,-dipheyltetrazo- lium bromide (MTT, Sigma Aldrich) reduction assay was 
performed for both cell lines. This method is one of the most frequently used for quantitating cell viability and 
it measures the conversion of MTT into purple-coloured formazan that is induced by redox activity of living 
cells: a decrease of cellular redox activity could be index of cell damage.33 
Cultured cells were detached using 0.1% Trypsin/EDTA solution (Sigma Aldrich) and diluted to a final 
concentration of 5 × 103 cells 100 μL−1. The cell suspension was trans- ferred into 96-well plates with DMEM 
(Lonza, Basel, Switzerland), 10% FBS (Sigma Aldrich), 2% penicilllin– streptomicin– amphotericin B solu- 
tion (Sigma Aldrich) and 2% L-glutamine (Sigma Aldrich). Each drug was tested in two different experimental 
sessions and three plates were pre- pared per each experimental session (n = 6). To evaluate the background 
adsorption, the first row of every plate remained cell-free as blank control. 
  
In the second row, cells were seeded in absence of any drug as internal control. The remaining part of the 
plates was used to test TRPV1 ligands. After an overnight incubation at 37 ◦C and 5% CO2, the medium used 
for the seeding was replaced by a medium prepared with DMEM, 5% FBS, 2% penicilllin– streptomicin– 
amphotericin B solution, 2% L-glutamine with the addition of increasing con- centrations of the following 
TRPV1 ligands: Cap- saicin and capsazepine (partial agonist and antago- nist, respectively, Sigma Aldrich) 
(10 − 10 –10−4M), resiniferatoxin (RTX) and 5-iodo-resiniferatoxin (5-I-RTX) (pure agonist and antagonist, 
respec- tively, Sigma Aldrich) (10−10 –10−6M). Plates were incubated at 37 ◦C at 5% CO2 for 24, 48 and 
72h. At each experimental time point, 20 μL of MTT (Sigma Aldrich) solution (4 mg mL−1) were added to 
each well, except to the free-cell blank wells, and plates were incubated at 37 ◦C and 5% CO2 for 4h. At the 
end of the incubation period, the medium containing the MTT solution was discarded and 100 μL of dimethyl 
sulfoxide (DMSO, Sigma Aldrich) were added in order to dissolve the formazan crys- tals. The plates were 
further incubated for 10 min at room temperature and then read using a plate reader (Powerwave X, Bio-Teck, 
Winooski, VT, USA) at a wavelength of 570 nm. 
The results obtained by the proliferation assays were statistically analysed using a computer programme 
(GraphPad Prism Software, San Diego, CA, USA), applying the Kruskal– Wallis test and a Dunn’s post-test 




Western blotting analysis indicated that the TRPV1 protein is expressed in MCF-7 cells as shown by the high 
density signal corresponding to the molecular weight of 100 kDa, in accordance with the mass of human 
TRPV1 (Fig. 1A).34 The signal corresponding to 100 kDa was also recognizable in the Western blotting 
analysis of CF.41 cells (Fig. 1B). The same signal was present in positive control (lysate of rat urinary bladder). 
Fig. 1C shows the signal corresponding to β-actin, used as endogenous control. 
 
Proliferation assays 
MCF-7 proliferation assay data are summarized in Figs 2– 5. All tested agonists and antagonists induced a 
significant decrease (P < 0.05) of growth rate in treated cells compared with controls. RTX showed a 
characteristic time-dependent behaviour (Fig. 4). As far as CF.41 cells are concerned results are presented in 
Figs 6– 9. The partial agonist (capsaicin) and the partial antagonist (capsazepine) caused a significant increase 
(P < 0.05) of CF.41 cell proliferation. By contrast, RTX and 5-I-RTX did not induce any significant effect on 
cell growth rate. 
 
Discussion 
To our knowledge, this is the first study demon- strating the expression of TRPV1 in CF.41 cells, while TRPV1 
in MCF-7 cells had already been identified by Barbero et al.35 in 2006. Increased expression of TRPV1 is 
associated with a better prognosis of patients with hepatocellular carci- noma, whereas expression of TRPV1 
is decreased in the urothelium of patients with advanced stage transitional cell carcinoma, suggesting that 
TRPV1 might function as a tumour suppressor and nega- tively control tumour progression.36 Different TRP 
channels are also expressed in human breast can- cer cells and cell lines such as MCF-7 and their 
overexpression compared to normal gland can be considered a suitable prognostic marker.37 It has been 
suggested that the receptor-mediated anti-tumour activity is associated with induction of apoptosis following 
activation of TRPV1 and changes in cell calcium influx.38 Calcium is an important intracellular messenger 
that regulates many physiological functions such as cellular dif- ferentiation, proliferation and apoptosis. 
Abnor- mal functioning of calcium signalling pathways may occur during cancerogenesis. Therefore, cal- cium 
channels with increased expression and/or activity in cancer could potentially serve as anti- cancer therapeutic 
targets. Recent investigations have suggested that besides proapoptotic action, the activation of TRPV1 leads 
to anti-angiogenic, anti-migrative, anti-adhesive and anti-metastatic effects.39 As TRPV1 is implicated in cell 
pro- liferation and pain modulation, a number of studies have been performed to describe the bind- ing 
characteristics and clinical efficacy of selective TRPV1 agonists and antagonists.40 Capsaicin and RTX are 
selective TRPV1 agonists and cause TRPV1 desensitization after activation while cap- sazepine and 5-iodo-
resinferatoxin are selective TRPV1 antagonists inducing a functional block of TRPV1 receptor.41 In our study, 
all tested ago- nists and antagonists caused a significant decrease (P < 0.05) in MCF-7 cell proliferation. By 
contrast, capsaicin and capsazepine induced a significant increase (P < 0.05) in CF.41 cell proliferation. These 
findings might account for species-specific differences in TRPV1 pharmacological proper- ties. In rodents, 
TRPV1 is activated by capsaicin and residues Arg114 and Glu761 in the intra- cellular N- and C-termini have 
been recognized as agonist binding sites.42 Unlike the murine one, the avian form of TRPV1 is not activated 
by capsaicin and the agonist binding sites are represented by residues Tyr511 and Thr550 in the third and fifth 
transmembrane domains.21 Moreover, species-dependent behaviour has been observed also for antagonists. 
According to Premkumar and Sikand,43 the TRPV1 competitive antagonist capsazepine inhibits the acid-
induced activation of human TRPV1, but exhibits no effects on acid-induced activation of rat TRPV1. The 
compound can inhibit heat-induced TRPV1 activation both in humans and rat. Besides this, it has been 
demonstrated that TRPV1 mutations can lead to changes in TRPV1 responses to agonist stimulation. Mutations 
at the sixth TRPV1 transmembrane domain can cause, for example, the reduction of 3[H]resiniferatoxin- 
binding affinity and mutations on pore domain significantly decrease the sensitivity to capsaicin.44 A further 
hypothesis to explain the different effects induced by TRPV1 agonists and antagonists on MCF-7 and CF.41 
proliferation might be the pos- sible interaction of capsaicin and capsazepine with other TRP or non-TRP 
receptors. Hwang et al.41 found that capsaicin might act as co-carcinogen on 12-O-tetradecanoylphorbol-13-
acetate (TPA)- induced skin carcinogenesis through the epidermal growth factor receptor. As the MTT 
proliferation assay does not provide information concerning the molecular mechanisms involved in TRPV1 
responses, further studies are needed to under- stand differences in human and canine breast cancer cell 
proliferation upon TRPV1 agonist and antagonist stimulation. The results of proliferation assays performed on 
MCF-7 confirm the potential of TRPV1 agonists as anti-cancer drugs. Interest- ingly, capsaicin was shown to 
inhibit human cancer hormone-resistant cells and to provide chemopre- ventive effects.45 Moreover, it was 
demonstrated that capsaicin is able to mediate cell death of T24 (human bladder cancer) and A172 (human 
glioma) cell lines.46,47 Even if the results of proliferation assays on MCF-7 cells seem to suggest that also 
TRPV1 antagonists could be used in cancer treat- ment, their use should be carefully considered: the systemic 
administration of TRPV1 antagonists could lead to the change of body temperature, gas- trointestinal and 
cardiovascular functions.43 Fur- thermore, the blockade of TRPV1 has been shown to increase its own 
expression, thereby raising the possibility of rebound effects.43 Therefore, TRPV1- mediated effects onhuman 
and canine breast cancer cells should be encouraged. 
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